Brind.

Isomorphic Labs and MSD Partner on AI-Driven Oncology Drug Discovery

2 reports, 1 independent Updated Thu 12:15
No new developments lately Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Isomorphic Labs and MSD announced a research collaboration to discover therapeutic small molecule candidates against an oncology target. Isomorphic Labs will apply its proprietary drug design engine and use select proprietary data sets supplied by MSD to perform *in silico* predictions and deliver molecular designs. MSD will be responsible for the preclinical, clinical, manufacturing, and commercialization of any products resulting from the collaboration.

From finanznachrichten.de

Why it matters

Some supportBrind's analysis of the reports

The collaboration combines Isomorphic Labs' AI approach to drug discovery with MSD's proprietary data resources and deep discovery experience. Under the agreement, Isomorphic Labs receives an upfront payment, is eligible for payments based on milestones, and will receive tiered royalties on net sales. MSD will manage the commercialization of any products derived from the partnership.

From finanznachrichten.de

Who's involved

  • Isomorphic LabsAI-first drug design and development company applying its engine to the collaboration.
  • MSDCompany responsible for preclinical, clinical, manufacturing, and commercialization of derived products.

Keep exploring

The entities involved

  • Isomorphic Labs

    British multinational artificial intelligence company

    Nothing else this week.

  • MSD

    company in Rome, Italy

    Nothing else this week.

Related events

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story